Aredo JV - Search Results

1

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.

Ji J, Aredo JV, Piper-Vallillo A, Huppert L, Rotow JK, Husain H, Stewart S, Cobb R, Wakelee HA, Blakely CM, Wong ML, Gubens MA, Madani MH, Digumarthy SR, McCoach C, Piotrowska Z, Neal JW, Riess JW. Ji J, et al. Among authors: aredo jv. JTO Clin Res Rep. 2023 Jan 10;4(3):100459. doi: 10.1016/j.jtocrr.2022.100459. eCollection 2023 Mar. JTO Clin Res Rep. 2023. PMID: 36879929 Free PMC article.

2

Beneficial Effects of Dry Needling for Treatment of Chronic Myofascial Pain Persist for 6 Weeks After Treatment Completion.

Gerber LH, Sikdar S, Aredo JV, Armstrong K, Rosenberger WF, Shao H, Shah JP. Gerber LH, et al. Among authors: aredo jv. PM R. 2017 Feb;9(2):105-112. doi: 10.1016/j.pmrj.2016.06.006. Epub 2016 Jun 11. PM R. 2017. PMID: 27297448 Free PMC article.

3

Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: A cross-sectional study.

Phan VT, Stratton P, Tandon HK, Sinaii N, Aredo JV, Karp BI, Merideth MA, Shah JP. Phan VT, et al. Among authors: aredo jv. Eur J Pain. 2021 Apr;25(4):831-840. doi: 10.1002/ejp.1713. Epub 2021 Jan 8. Eur J Pain. 2021. PMID: 33326662 Free PMC article.

4

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA. Aredo JV, et al. Lung Cancer. 2019 Jul;133:144-150. doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15. Lung Cancer. 2019. PMID: 31200821 Free PMC article.

5

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA. Aredo JV, et al. Lung Cancer. 2019 Nov;137:159-160. doi: 10.1016/j.lungcan.2019.08.020. Epub 2019 Aug 26. Lung Cancer. 2019. PMID: 31492438 No abstract available.

6

Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.

Aredo JV, Diehn M, Berry GJ, Wakelee HA. Aredo JV, et al. Clin Lung Cancer. 2021 Sep;22(5):e673-e677. doi: 10.1016/j.cllc.2020.12.005. Epub 2020 Dec 19. Clin Lung Cancer. 2021. PMID: 33451914 No abstract available.

7

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.

Hellyer JA, Aredo JV, Das M, Ramchandran K, Padda SK, Neal JW, Wakelee HA. Hellyer JA, et al. Among authors: aredo jv. J Thorac Oncol. 2021 May;16(5):868-872. doi: 10.1016/j.jtho.2020.12.020. Epub 2021 Feb 1. J Thorac Oncol. 2021. PMID: 33539970 Free article.

8

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, Wakelee HA. Aredo JV, et al. J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi: 10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12. J Thorac Oncol. 2021. PMID: 33588109 Free article.

9

Metabolomic profiling for second primary lung cancer: A pilot case-control study.

Aredo JV, Purington N, Su L, Luo SJ, Diao N, Christiani DC, Wakelee HA, Han SS. Aredo JV, et al. Lung Cancer. 2021 May;155:61-67. doi: 10.1016/j.lungcan.2021.03.007. Epub 2021 Mar 11. Lung Cancer. 2021. PMID: 33743383 Free PMC article.

10

A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.

Aredo JV, Wakelee HA, Han SS. Aredo JV, et al. J Thorac Oncol. 2021 Aug;16(8):e59-e60. doi: 10.1016/j.jtho.2021.05.008. J Thorac Oncol. 2021. PMID: 34304856 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page